Healthcare / Diagnostics & ResearchParis
$2.87
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-3.7M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$11M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-4653.8%
↓Gross Margin
97.8%
↑Debt/Equity
-1.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+63.0%
FCF CAGR
—
FCF margin
-603.0%
FCF / Net income
-0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $618058.0 · net income $198.6M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $618058.00 | $618058.00 | $317833.00 | $288683.00 | $142669.00 |
| Net Income | $198.6M | $198.6M | $-4.2M | $-3.6M | $-3.4M |
| EBITDA | $-4.0M | $-4.0M | $-3.8M | $-3.5M | $-3.5M |
| EPS | — | — | -1.14 | -1.00 | -0.93 |
| Gross Margin | 97.8% | 97.8% | 96.6% | 87.5% | 65.4% |
| Operating Margin | -645.0% | -645.0% | -1208.2% | -1211.7% | -2460.5% |
| Net Margin | 32137.4% | 32137.4% | -1326.7% | -1262.9% | -2385.6% |
| Balance Sheet | |||||
| Debt/Equity | -1.16 | -1.16 | -1.90 | 7.41 | -3.28 |
| Current Ratio | 0.45 | 0.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-4.3M | $-3.1M | $-3.8M |
| Returns | |||||
| ROE | -4653.8% | -4653.8% | 107.7% | -381.0% | 217.4% |
| Valuation | |||||
| P/B | — | — | — | 22.86 | — |
| Growth & Yield | |||||
| Revenue Growth | 94.5% | 94.5% | 10.1% | 102.3% | — |
| EPS Growth | — | — | -14.0% | -7.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.14 → n/d
Residual
-22.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.